GSK sues Pfizer and BioNTech over mRNA billions – The Pharma Letter

UK pharma major GSK (LSE: GSK) has launched a lawsuit against Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX).

The suit accuses the companies of breaching GSK mRNA vaccine technology patents in their development of the Comirnaty vaccine for COVID-19. The jab swiftly became a top-selling pharma product to help the world to move on from the pandemic, earning Pfizer $43 billion in global revenue in one year alone.

GSK claims that the research in question

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user pleaselogin. If your trial has come to an end, you cansubscribe here.

Try before you buy

All the news that moves the needle in pharma and biotech. Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters. Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. Daily roundup of key events in pharma and biotech. Monthly in-depth briefings on Boardroom appointments and M&A news. Choose from a cost-effective annual package or a flexible monthly subscription.

See more here:

GSK sues Pfizer and BioNTech over mRNA billions - The Pharma Letter